Trevi Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, null, 44.78, 218.87 ], "ebit_estimate": [ -79.34, -107.58, -132.66, -136.27, -9.88 ], "ebitda_estimate": [ -74.52, -96.11, -132.44, -133.39, -19.27 ], "net_income_estimate": [ -73.34, -98.94, -123.36, -144.18, -24.91 ], "per_share_eps_estimate": [ -0.48, -0.59, -0.7, -0.78, 0.07 ], "eps_nri_estimate": [ -0.47, -0.59, -0.7, -0.78, -0.02 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 1.81, 1.28, 2.27, null, null ], "pretax_income_estimate": [ -73.35, -98.94, -123.36, -129.71, -24.51 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -26.82, -36.8, -38.07, null, null ], "gross_margin_estimate": [ 100, 91.67, 87.5, 86.67, 87.5 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 251.34 ], "long_term_growth_rate_mean": -29.34, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -29.31, "future_eps_nri_estimate_growth": -29.34, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -38.72, "future_ebitda_estimate_growth": -44.08, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -41.59, "future_pretax_income_estimate_growth": -41.53, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -10.61, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -17.92, -22.18, -24.68, -35.18, -38.01, -41.36, -44.9 ], "ebitda_estimate": [ -17.86, -20.81, -22.05, null, null, null, null ], "net_income_estimate": [ -16.61, -20.57, -23.06, -32.44, -35.55, -39.22, -43.11 ], "per_share_eps_estimate": [ -0.11, -0.13, -0.15, -0.16, -0.18, -0.19, -0.21 ], "eps_nri_estimate": [ -0.11, -0.13, -0.14, -0.16, -0.18, -0.19, -0.21 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -16.61, -20.57, -23.06, -32.44, 35.55, -39.22, -43.11 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 95, 95, 95, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -29.34, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -29.31, "future_eps_nri_estimate_growth": -29.34, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -38.72, "future_ebitda_estimate_growth": -44.08, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -41.59, "future_pretax_income_estimate_growth": -41.53, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -10.61, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }